Stock Detail
CUBIST PHARMACEUTICALS INC
Drug Manufacturers Other
CBST @ Yahoo Finance | CBST Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $36.80 | $37.70 | $-0.19 | -0.51% | 0.00 | $36.99 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $36.74 | $36.56 | 1.06M | 2.27B | 1.21M | 64.23 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 38.16 | 37.48 | 37.02 | 36.34 | 35.88 |
Stock Profile
Cubist Pharmaceuticals, Inc. engages in the research, development, and commercialization of products for anti-infective and acute care needs market. Its principal product, Cubicin, is approved in the United States for the treatment of skin and skin structure infections caused by certain gram-positive bacteria. The company's pipeline includes HepeX-B, a monoclonal antibody biologic that is in second of two Phase 2 trials, for the prevention of infection by Hepatitis B virus in liver transplant patients, as well as research efforts focused on members of the lipopeptide class of molecules. Cubist has a licensing agreement with XTL Biopharmaceuticals, Ltd., for the development and commercialization of HepeX-B. The company was founded in 1992 and is headquartered in Lexington, Massachusetts.